Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. Q-Line Biotech's Revenue for the
six
months ended in Mar. 2025 was ₹3,138 Mil. Q-Line Biotech's Total Assets for the quarter that ended in Mar. 2025 was ₹3,974 Mil. Therefore, Q-Line Biotech's Asset Turnover for the quarter that ended in Mar. 2025 was 0.79.
Asset Turnover is linked to ROE % through Du Pont Formula. Q-Line Biotech's annualizedROE % for the quarter that ended in Mar. 2025 was 31.99%. It is also linked to ROA % through Du Pont Formula. Q-Line Biotech's annualizedROA % for the quarter that ended in Mar. 2025 was 14.16%.
Note:
The Net Income data used here is two times the semi-annual (Mar. 2025) net income data. The Revenue data used here is two times the semi-annual (Mar. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
Q-Line Biotech's annulizedROA % for the quarter that ended in Mar. 2025 is
Note:
The Net Income data used here is two times the semi-annual (Mar. 2025) net income data. The Revenue data used here is two times the semi-annual (Mar. 2025) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
Q-Line Biotech Asset Turnover Related Terms
Q-Line Biotech Asset Turnover Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Asset Turnover Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Asset Turnover
0.73
0.69
0.79
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Asset Turnover
0.73
0.69
0.79
NSE:QLINE vs ABT, SYK, MDT: Asset Turnover Comparison
For the Medical Devices subindustry, Q-Line Biotech's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Asset Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Asset Turnover distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
Q-Line Biotech (NSE:QLINE) has a Asset Turnover of 0.79 as of Mar. 2025. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Q-Line Biotech and its competitors.
Is Q-Line Biotech's Asset Turnover too high?
Q-Line Biotech's current Asset Turnover is 0.79. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Asset Turnover compare to ABT and SYK?
Q-Line Biotech's Asset Turnover of 0.79 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Medical Devices & Instruments company?
A good Asset Turnover depends on the Medical Devices & Instruments industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on Q-Line Biotech and its competitors. Q-Line Biotech's current Asset Turnover is 0.79. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Asset Turnover of 0.79. The current Asset Turnover is 0.79. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Asset Turnover is 0.79 as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 